Sugi Predict

Sugi Predict / Compounds / SCHEMBL114538

SCHEMBL114538

SCHEMBL114538

CC(C)(C)OC(=O)N1CCN(c2ccc(C(F)(F)F)cc2N)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.54
▸ LMNA P02545 2/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ GPR119 Q8TDV5 3/20 0.53
▸ MAPT P10636 3/20 0.53
▸ SMARCA2 P51531 1/20 0.51
▸ SMARCA4 P51532 1/20 0.51
▸ PBRM1 Q86U86 1/20 0.51
▸ MC4R P32245 1/20 0.46
▸ CFTR P13569 1/20 0.46
▸ TACR1 P25103 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ STS P08842 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ ENPP2 Q13822 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301736 1.00 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EGPR119MAPT
SCHEMBL6628461 0.95 MAPT (0.57) ALDH1A1LMNAKDM4EGPR119MAPT
SCHEMBL14453584 0.87 GPR119 (0.55) ALDH1A1LMNAGPR119MAPTSMARCA2
SCHEMBL3923112 0.86 GPR119 (0.54) ALDH1A1LMNAGPR119MAPTTACR1
SCHEMBL4422111 0.86 GPR119 (0.54) ALDH1A1LMNAGPR119MAPTSMARCA2
SCHEMBL3922455 0.86 GPR119 (0.69) ALDH1A1LMNAGPR119MAPTMC4R
SCHEMBL31142873 0.86 GPR119 (0.69) ALDH1A1LMNAGPR119MAPTMC4R
SCHEMBL115105 0.85 GPR119 (0.53) ALDH1A1LMNAGPR119MAPTSMARCA2
SCHEMBL13076730 0.85 GPR119 (0.53) ALDH1A1LMNAGPR119MAPTSMARCA2
SCHEMBL31250021 0.85 ALDH1A1 (0.57) ALDH1A1LMNAMAPTSMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182311-B1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LTD (GB) 2025-06-04 — — EP disclosed
US-20240300929-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LTD (GB) 2024-09-12 — — US disclosed
US-12024504-B2 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases EXONATE LIMITED (GB) 2024-07-02 — — US disclosed
CN-116075506-A 1-methyl-1H-pyrazol-3-yl derivatives for the treatment of neovascular diseases 埃克森纳特有限公司 2023-05-05 — — CN disclosed
US-20220411412-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LIMITED (GB) 2022-12-29 — — US disclosed
US-20220411412-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LIMITED (GB) 2022-12-29 — — US disclosed
CN-109912514-B (2-heteroarylaminophenyl) nitrogen heterocyclic derivative and application thereof 广东东阳光药业有限公司 2022-11-18 — — CN disclosed
WO-2022013555-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES EXONATE LIMITED (GB) 2022-01-20 — — WO disclosed
EP-3131886-B1 PIPERAZINE DERIVATIVES FOR TREATING DISORDERS EXONATE LTD (GB) 2020-09-09 — — EP disclosed
US-9932330-B2 Piperazine derivatives for treating disorders THE UNIVERSITY OF NOTTINGHAM (GB) 2018-04-03 — — US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — US disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 — — WO disclosed
CN-101679266-A PIM kinase inhibitors and methods of their use NOVARTIS AG 2010-03-24 — — CN disclosed
EP-2132177-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE Novartis Ag (CH) 2009-12-16 — — EP disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 — — WO disclosed
WO-2008106692-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-04 — — WO disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS ALDH1A1 764/4885LMNA 2867/4885KDM4E 2459/4885
US-20220411412-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES VEGFA, FLT4, FLT1 ALDH1A1 1874/4885LMNA 2008/4885KDM4E 1107/4885
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 ALDH1A1 1298/4885LMNA 4200/4885KDM4E 3994/4885
US-20240300929-A1 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES VEGFA, FLT4, FLT1 ALDH1A1 1874/4885LMNA 2008/4885KDM4E 1107/4885
US-12024504-B2 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases VEGFA, FLT4, FLT1 ALDH1A1 1874/4885LMNA 2008/4885KDM4E 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.